Splicing dysregulation as a driver of breast cancer.
View/ Open
Date
2018-09-01Author
Read, A
Natrajan, R
Type
Journal Article
Metadata
Show full item recordAbstract
Breast cancer is known to be a heterogeneous disease driven by a large repertoire of molecular abnormalities, which contribute to its diverse clinical behaviour. Despite the success of targeted therapy approaches for breast cancer patient management, there is still a lack of the molecular understanding of aggressive forms of the disease and clinical management of these patients remains difficult. The advent of high-throughput sequencing technologies has paved the way for a more complete understanding of the molecular make-up of the breast cancer genome. As such, it is becoming apparent that disruption of canonical splicing within breast cancer governs its clinical progression. In this review, we discuss the role of dysregulation of spliceosomal component genes and associated factors in the progression of breast cancer, their role in therapy resistance and the use of quantitative isoform expression as potential prognostic and predictive biomarkers with a particular focus on oestrogen receptor-positive breast cancer.
Collections
Subject
Humans
Breast Neoplasms
Prognosis
Alternative Splicing
Drug Resistance, Neoplasm
Female
Biomarkers
Research team
Functional Genomics
Language
eng
Date accepted
2018-05-30
License start date
2018-09
Citation
Endocrine-related cancer, 2018, 25 (9), pp. R467 - R478
Publisher
BIOSCIENTIFICA LTD